Parathyroid Carcinoma Medication

1. Fingeret AL. Contemporary Evaluation and Management of Parathyroid Carcinoma. JCO Oncol Pract. 2021 Jan. 17 (1):17-21. [QxMD MEDLINE Link].

2. Li Y, Simonds WF. Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer. 2016 Jun. 23 (6):R229-47. [QxMD MEDLINE Link]. [Full Text].

3. Shattuck TM, Valimaki S, Obara T. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003 Oct 30. 349(18):1722-9. [QxMD MEDLINE Link].

4. Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, et al. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight. 2017 Mar 23. 2 (6):e92061. [QxMD MEDLINE Link]. [Full Text].

5. Lim S, Elston MS, Gill AJ, Marsh DJ, Conaglen JV. Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy. Intern Med J. 2011 Sep. 41(9):695-9. [QxMD MEDLINE Link].

6. Sulaiman L, Haglund F, Hashemi J, Obara T, Nordenström J, Larsson C, et al. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors. PLoS One. 2012. 7(9):e46325. [QxMD MEDLINE Link]. [Full Text].

7. Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol. 1999 Apr. 12(4):412-6. [QxMD MEDLINE Link].

8. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, Simonds WF. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene. 2005 Feb 10. 24(7):1272-6. [QxMD MEDLINE Link].

9. Cryns VL, Thor A, Xu HJ. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994 Mar 17. 330(11):757-61. [QxMD MEDLINE Link].

10. Haven CJ, van Puijenbroek M, Tan MH, Teh BT, Fleuren GJ, van Wezel T, et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf). 2007 Sep. 67(3):370-6. [QxMD MEDLINE Link].

11. van der Tuin K, Tops CMJ, Adank MA, Cobben JM, Hamdy NAT, Jongmans MC, et al. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2017 Dec 1. 102 (12):4534-4540. [QxMD MEDLINE Link].

12. Lo WM, Good ML, Nilubol N, Perrier ND, Patel DT. Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma. Ann Surg Oncol. 2018 Sep. 25 (9):2535-2540. [QxMD MEDLINE Link].

13. van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, et al. Carcinoma of endocrine organs: results of the RARECARE project. Eur J Cancer. 2012 Sep. 48(13):1923-31. [QxMD MEDLINE Link].

14. Kong SH, Kim JH, Park MY, Kim SW, Shin CS. Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort. J Cancer Res Clin Oncol. 2021 Mar 18. [QxMD MEDLINE Link].

15. Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010 Aug. 17(8):2156-74. [QxMD MEDLINE Link].

16. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007 May 1. 109(9):1736-41. [QxMD MEDLINE Link].

17. Douglas L. Fraker. Chapter 44 - Cancer of the Endocrine System, Section 3: Parathyroid Tumors. Vincent T. DeVita, Jr., Theodore S. Lawrence, Steven A. Rosenberg. Cancer: Principles & Practice of Oncology. 8th. Philadelphia: Lippincott Williams & Wilkins; 2008. 1682-1690.

18. Wynne AG, van Heerden J, Carney JA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992 Jul. 71(4):197-205. [QxMD MEDLINE Link].

19. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004 Aug. 26(8):716-26. [QxMD MEDLINE Link].

20. Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg. 1985 Apr. 149(4):522-7. [QxMD MEDLINE Link].

21. Hakaim AG, Esselstyn CB Jr. Parathyroid carcinoma: 50-year experience at The Cleveland Clinic Foundation. Cleve Clin J Med. 1993 Jul-Aug. 60(4):331-5. [QxMD MEDLINE Link].

22. Favia G, Lumachi F, Polistina F, D'Amico DF. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg. 1998 Dec. 22(12):1225-30. [QxMD MEDLINE Link].

23. Flye MW, Brennan MF. Surgical resection of metastatic parathyroid carcinoma. Ann Surg. 1981 Apr. 193(4):425-35. [QxMD MEDLINE Link].

24. Schaapveld M, Jorna FH, Aben KK, Haak HR, Plukker JT, Links TP. Incidence and prognosis of parathyroid gland carcinoma: A population-based study in The Netherlands estimating the preoperative diagnosis. Am J Surg. 2011 Aug 20. [QxMD MEDLINE Link].

25. Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011 Dec. 96(12):3679-86. [QxMD MEDLINE Link].

26. James BC, Aschebrook-Kilfoy B, Cipriani N, Kaplan EL, Angelos P, Grogan RH. The Incidence and Survival of Rare Cancers of the Thyroid, Parathyroid, Adrenal, and Pancreas. Ann Surg Oncol. 2016 Feb. 23 (2):424-33. [QxMD MEDLINE Link].

27. Asare EA, Sturgeon C, Winchester DJ, Liu L, Palis B, Perrier ND, et al. Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015 Nov. 22 (12):3990-5. [QxMD MEDLINE Link].

28. Christakis I, Bussaidy N, Clarke C, Kwatampora LJ, Warneke CL, Silva AM, et al. Differentiating Atypical Parathyroid Neoplasm from Parathyroid Cancer. Ann Surg Oncol. 2016 Sep. 23 (9):2889-97. [QxMD MEDLINE Link].

29. Karakas E, Müller HH, Lyadov VK, Luz S, Schneider R, Rothmund M, et al. Development of a formula to predict parathyroid carcinoma in patients with primary hyperparathyroidism. World J Surg. 2012 Nov. 36(11):2605-11. [QxMD MEDLINE Link].

30. Hu Y, Zhang X, Cui M, Su Z, Wang M, Liao Q, et al. Verification of candidate microRNA markers for parathyroid carcinoma. Endocrine. 2018 May. 60 (2):246-254. [QxMD MEDLINE Link].

31. van Baardwijk A, de Jong J, Arens A, Thimister P, Verseput G, Kremer B, et al. False-positive FDG-PET scan due to brown tumours. Eur J Nucl Med Mol Imaging. 2006 Mar. 33(3):393-4. [QxMD MEDLINE Link].

32. Weaver TD, Shakir MKM, Hoang TD. Hyperparathyroidism-Jaw Tumor Syndrome. Case Rep Oncol. 2021 Jan-Apr. 14 (1):29-33. [QxMD MEDLINE Link]. [Full Text].

33. Kim J, Horowitz G, Hong M, Orsini M, Asa SL, Higgins K. The dangers of parathyroid biopsy. J Otolaryngol Head Neck Surg. 2017 Jan 7. 46 (1):4. [QxMD MEDLINE Link]. [Full Text].

34. Guarnieri V, Battista C, Muscarella LA, Bisceglia M, de Martino D, Baorda F, et al. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol (Dordr). 2012 Dec. 35(6):411-22. [QxMD MEDLINE Link].

35. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009 Feb. 94(2):434-41. [QxMD MEDLINE Link].

36. Erovic BM, Harris L, Jamali M, Goldstein DP, Irish JC, Asa SL, et al. Biomarkers of parathyroid carcinoma. Endocr Pathol. 2012 Dec. 23(4):221-31. [QxMD MEDLINE Link].

37. Fang SH, Lal G. Parathyroid cancer. Endocr Pract. 2011 Mar-Apr. 17 Suppl 1:36-43. [QxMD MEDLINE Link].

38. Schulte KM, Gill AJ, Barczynski M, Karakas E, Miyauchi A, Knoefel WT, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012 Aug. 19(8):2620-8. [QxMD MEDLINE Link].

39. Limberg J, Stefanova D, Ullmann TM, Thiesmeyer JW, Bains S, Beninato T, et al. The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis. Ann Surg Oncol. 2021 Jan. 28 (1):502-511. [QxMD MEDLINE Link]. [Full Text].

40. Jumpertz von Schwartzenberg R, Elbelt U, Ventz M, Mai K, Kienitz T, Maurer L, et al. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep. 2015. 2015:150082. [QxMD MEDLINE Link].

41. Fountas A, Andrikoula M, Giotaki Z, Limniati C, Tsakiridou E, Tigas S, et al. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia. Endocr Pract. 2015 May. 21 (5):468-73. [QxMD MEDLINE Link].

42. Silva-Figueroa A, Villalobos P, Williams MD, Bassett RL Jr, Clarke CN, Lee JE, et al. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery. 2018 Jul 19. [QxMD MEDLINE Link].

43. [Guideline] Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016 Oct 1. 151 (10):959-968. [QxMD MEDLINE Link]. [Full Text].

44. Schulte KM, Talat N, Miell J, Moniz C, Sinha P, Diaz-Cano S. Lymph node involvement and surgical approach in parathyroid cancer. World J Surg. 2010 Nov. 34(11):2611-20. [QxMD MEDLINE Link].

Lawrence T Kim, MD, FACS, FACE Professor, Department of Surgery, Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill School of Medicine; Member, UNC Lineberger Comprehensive Cancer Center

Lawrence T Kim, MD, FACS, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American Association of Endocrine Surgeons, American College of Endocrinology, American College of Surgeons, American Thyroid Association, International Association of Endocrine Surgeons, Parkland Surgical Society, Society of Surgical Oncology, Southern Surgical Association, Surgical Discovery Club

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Neetu Radhakrishnan, MD Medical Oncologist, Kettering Cancer Care

Neetu Radhakrishnan, MD is a member of the following medical societies: American College of Physicians, American Society of Clinical Oncology, American Society of Hematology

Disclosure: Nothing to disclose.

Sanjiv S Agarwala, MD Chief of Oncology and Hematology, St Luke's Cancer Center, St Luke's Hospital and Health Network; Professor, Temple University Shool of Medicine

Sanjiv S Agarwala, MD is a member of the following medical societies: American Association for Cancer Research, American Head and Neck Society, European Society for Medical Oncology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group

Disclosure: Received honoraria from BMS for speaking and teaching; Received consulting fee from Novartis for consulting; Received consulting fee from Merck for consulting.

Wendy Hu, MD Consulting Staff, Department of Hematology/Oncology and Bone Marrow Transplantation, Huntington Memorial Medical Center

Wendy Hu, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Blood and Marrow Transplantation, American Society of Hematology, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article